Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naïve Parkinson's disease
Identifieur interne : 000893 ( Main/Exploration ); précédent : 000892; suivant : 000894Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naïve Parkinson's disease
Auteurs : Isabelle Boileau [Canada, Niger] ; Mark Guttman [Canada] ; Pablo Rusjan [Canada] ; John R. Adams [Canada] ; Sylvain Houle [Canada] ; Junchao Tong [Canada] ; Oleh Hornykiewicz [Autriche] ; Yoshiaki Furukawa [Canada] ; Alan A. Wilson [Canada] ; Shitij Kapur [Canada] ; Stephen J. Kish [Canada]Source :
- Brain [ 0006-8950 ] ; 2009-05.
Abstract
The D3 dopamine (DA) receptor is a member of the D2-like DA receptor family. While the D2 receptor is abundant especially in motor-regions of the striatum, the D3 receptor shows a relative abundance in limbic regions and globus pallidus. This receptor is of current interest in neurology because of its potential involvement in psychiatric and motor complications in Parkinson's disease and the possibility that dopamine D3-preferring agonist therapy might delay progression of the disorder. Preclinical data indicate that striatal levels of the D3 (but not the D2) DA receptor are decreased following lesion of nigrostriatal DA neurons; at present, there are no in vivo data on this receptor subtype in Parkinson's disease. The objective of this positron emission tomography study was to compare [11C]-(+)-PHNO (D3 versus D2 preferring) and [11C]raclopride (D3 = D2) binding in brain of non-depressed, non-demented, dopaminergic drug-naïve patients with early-stage Parkinson's disease (n = 10), relative to matched-controls (n = 9). Parkinson's disease was associated with a trend for bilaterally decreased [11C]-(+)-PHNO (but not [11C]raclopride) binding in the D3-rich ventral striatum (−11%, P = 0.07) and significantly decreased binding in globus pallidus (−42%, P = 0.02). In contrast, in the primarily D2-populated putamen, both [11C]-(+)-PHNO (25%, P = 0.02) and [11C]raclopride (25%, P < 0.01) binding were similarly increased, especially on the side contra-lateral to the symptoms. In the midbrain, presumably containing D3 receptors localized to the substantia nigra, [11C]-(+)-PHNO binding was normal. Decreased [11C]-(+)-PHNO to [11C]raclopride ratio correlated with motor deficits and lowered-mood (P < 0.02). Our imaging data suggest that brain DA neuron loss in the human causes region-specific differential changes in DA D2 and D3 receptors with D3 receptor ‘downregulation’ possibly related to some motor and mood problems in Parkinson disease. D3 receptor levels might be a determinant vulnerability factor underlying side-effects associated with treatment; hence, these initial findings provide valuable baseline information to understand the role of D3 receptors in response to Parkinson's disease medication.
Url:
DOI: 10.1093/brain/awn337
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naïve Parkinson's disease</title><author><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name></author><author><name sortKey="Adams, John R" sort="Adams, John R" uniqKey="Adams J" first="John R." last="Adams">John R. Adams</name></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name></author><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A." last="Wilson">Alan A. Wilson</name></author><author><name sortKey="Kapur, Shitij" sort="Kapur, Shitij" uniqKey="Kapur S" first="Shitij" last="Kapur">Shitij Kapur</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DEF041624DF19D7C60365575178ED9222A503DC5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/brain/awn337</idno><idno type="url">https://api.istex.fr/document/DEF041624DF19D7C60365575178ED9222A503DC5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B11</idno><idno type="wicri:Area/Main/Curation">000971</idno><idno type="wicri:Area/Main/Exploration">000893</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naïve Parkinson's disease</title><author><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>3 Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>2 Centre for Movement Disorders, Markham, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>3 Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Adams, John R" sort="Adams, John R" uniqKey="Adams J" first="John R." last="Adams">John R. Adams</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>2 Centre for Movement Disorders, Markham, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>3 Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>4 Center for Brain Research, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A." last="Wilson">Alan A. Wilson</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>3 Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Kapur, Shitij" sort="Kapur, Shitij" uniqKey="Kapur S" first="Shitij" last="Kapur">Shitij Kapur</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>3 Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-05">2009-05</date><biblScope unit="volume">132</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1366">1366</biblScope><biblScope unit="page" to="1375">1375</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">DEF041624DF19D7C60365575178ED9222A503DC5</idno><idno type="DOI">10.1093/brain/awn337</idno><idno type="ArticleID">awn337</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The D3 dopamine (DA) receptor is a member of the D2-like DA receptor family. While the D2 receptor is abundant especially in motor-regions of the striatum, the D3 receptor shows a relative abundance in limbic regions and globus pallidus. This receptor is of current interest in neurology because of its potential involvement in psychiatric and motor complications in Parkinson's disease and the possibility that dopamine D3-preferring agonist therapy might delay progression of the disorder. Preclinical data indicate that striatal levels of the D3 (but not the D2) DA receptor are decreased following lesion of nigrostriatal DA neurons; at present, there are no in vivo data on this receptor subtype in Parkinson's disease. The objective of this positron emission tomography study was to compare [11C]-(+)-PHNO (D3 versus D2 preferring) and [11C]raclopride (D3 = D2) binding in brain of non-depressed, non-demented, dopaminergic drug-naïve patients with early-stage Parkinson's disease (n = 10), relative to matched-controls (n = 9). Parkinson's disease was associated with a trend for bilaterally decreased [11C]-(+)-PHNO (but not [11C]raclopride) binding in the D3-rich ventral striatum (−11%, P = 0.07) and significantly decreased binding in globus pallidus (−42%, P = 0.02). In contrast, in the primarily D2-populated putamen, both [11C]-(+)-PHNO (25%, P = 0.02) and [11C]raclopride (25%, P < 0.01) binding were similarly increased, especially on the side contra-lateral to the symptoms. In the midbrain, presumably containing D3 receptors localized to the substantia nigra, [11C]-(+)-PHNO binding was normal. Decreased [11C]-(+)-PHNO to [11C]raclopride ratio correlated with motor deficits and lowered-mood (P < 0.02). Our imaging data suggest that brain DA neuron loss in the human causes region-specific differential changes in DA D2 and D3 receptors with D3 receptor ‘downregulation’ possibly related to some motor and mood problems in Parkinson disease. D3 receptor levels might be a determinant vulnerability factor underlying side-effects associated with treatment; hence, these initial findings provide valuable baseline information to understand the role of D3 receptors in response to Parkinson's disease medication.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li><li>Niger</li></country><region><li>Ontario</li><li>Vienne (Autriche)</li></region><settlement><li>Toronto</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name></region><name sortKey="Adams, John R" sort="Adams, John R" uniqKey="Adams J" first="John R." last="Adams">John R. Adams</name><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><name sortKey="Kapur, Shitij" sort="Kapur, Shitij" uniqKey="Kapur S" first="Shitij" last="Kapur">Shitij Kapur</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A." last="Wilson">Alan A. Wilson</name></country><country name="Niger"><noRegion><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name></noRegion></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000893 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000893 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DEF041624DF19D7C60365575178ED9222A503DC5
|texte= Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naïve Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |